U.S. Mortgage Finance Stock News

If you have been following GEO Group lately, there is plenty to talk about. The company just reported a strong turnaround in its latest earnings, swinging from a loss last year to a solid profit and increased revenue. In addition, management updated full-year guidance to forecast much higher net income, largely due to a significant facility sale. The company also announced a $300 million share buyback program. These developments have put the company back in the spotlight and might have...

Construction Partners, Inc. recently announced strong third quarter results, reporting US$779.28 million in sales and US$44.05 million in net income, while reaffirming its full-year guidance and continuing active discussions around acquisitions and industry investments. The company's ongoing acquisition efforts and reaffirmed optimism about reshoring trends highlight its intention to expand both organically and through targeted deals in high-growth markets. We'll explore how the company's...

If you’re holding or considering shares of Booz Allen Hamilton Holding (BAH), you’ve just witnessed a major move. The company was awarded a five-year, single-award contract worth up to $1.58 billion to deliver intelligence analysis and support in the fight against weapons of mass destruction. This is not just another government services deal. It puts Booz Allen at the forefront of national security, working with top agencies such as the Defense Intelligence Agency and the Defense Threat...

RXO, Inc. reported its second quarter 2025 earnings on August 7, showing sales of US$1.42 billion compared to US$930 million a year earlier, while recording a net loss of US$9 million versus a US$7 million loss the previous year. Despite robust revenue growth, the company’s net losses widened year-over-year, highlighting ongoing profitability pressures even as sales expanded significantly. We'll examine how RXO's large sales increase amid continued losses could influence expectations for its...

If you are sitting on the fence about Eversource Energy stock, you are definitely not alone. The past year has seen some intriguing twists, from a near 15% YTD climb to a steadier, more cautious long-term performance. Eversource’s price movements have kept investors guessing, with short-term returns making up some ground after a tough multi-year stretch. Over the last month alone, the stock inched up 0.5%, and in the last quarter, it managed a 2.7% gain. While those numbers might not signal...

NYSE:XPEV 1 Year Share Price vs Fair Value Explore XPeng's Fair Values from the Community and select yours XPeng...

NasdaqCM:SNGX 1 Year Share Price vs Fair Value Explore Soligenix's Fair Values from the Community and select yours Just...

NasdaqGS:DAKT 1 Year Share Price vs Fair Value Explore Daktronics's Fair Values from the Community and select yours...

Advance Auto Parts ( NYSE:AAP ) Second Quarter 2025 Results Key Financial Results Revenue: US$2.01b (down 7.7% from 2Q...

If you are holding or eyeing Charter Communications stock right now, you are probably wondering if this is a moment of opportunity or caution. With the market always in flux, CHTR has certainly kept investors on their toes over the past year. After peaking, the share price has come back down significantly, sitting at $267.01 at the latest close. Over the last month, the stock slid by about 30%. The drop over a full year is even more striking, with a total return of -23%. It is not all gloom,...

NasdaqGS:TCOM 1 Year Share Price vs Fair Value Explore Trip.com Group's Fair Values from the Community and select yours...

NasdaqGS:FTNT 1 Year Share Price vs Fair Value Explore Fortinet's Fair Values from the Community and select yours The...

Arch Capital Group (ACGL) has quietly climbed by over 4% in the past month, enough to grab the attention of investors wondering if the move is just noise or a signal for something bigger. There is no single event driving this uptick: no acquisition announcement, earnings surprise, or dramatic shift in outlook. Even so, these steady gains can spark questions about whether the market is catching on to overlooked potential or simply adjusting to changes in risk sentiment for insurance...

If you have been eyeing Zeta Global Holdings and wondering whether now is the time to get in, you are definitely not alone. Investors and analysts alike have been paying close attention as the stock has made some impressive moves lately. Over the past three months, Zeta’s share price has surged about 45%, and it is up more than 21% in just the last month. For anyone on the fence, these kinds of jumps are usually a signal that something is shifting, whether it is heightened growth...

NasdaqGM:RICK 1 Year Share Price vs Fair Value Explore RCI Hospitality Holdings's Fair Values from the Community and...

Apple Hospitality REIT, Inc. announced its Board of Directors declared a regular monthly cash distribution of US$0.08 per share, payable September 15, 2025, to shareholders of record as of August 29, 2025, while also reporting lower second-quarter sales, revenue, and net income compared to the prior year. The company lowered its full-year 2025 financial outlook, citing softer booking trends and ongoing economic uncertainty, even as it continued share repurchases and maintained regular...

Hanover Insurance Group (THG) just priced a $500 million senior notes offering at a 5.50% rate. The company plans to use much of the proceeds to pay down more expensive debt coming due over the next year. For investors evaluating their options, this strategic refinancing signals management’s intention to strengthen the balance sheet and potentially improve earnings in the future. This type of event can also influence investor sentiment, as it offers insight into how the company approaches...

If you are trying to make sense of AMETEK and whether now is the right time to buy, hold, or even sell, you are not alone. With so many moving parts and headlines swirling, it can be tough to cut through the noise. The company’s stock has delivered a total return of more than 13% over the past year, and almost 90% over the past five years, making it a name that is hard to ignore in any serious portfolio. Recently, the price has continued its climb, closing at $185.20, just under 10% below the...

Amphastar Pharmaceuticals recently announced an exclusive license agreement with Nanjing Anji Biotechnology, securing U.S. and Canadian rights to develop and commercialize three proprietary peptide therapeutics, with total potential payments to Anji reaching up to US$453 million over the life of the deal. This collaboration grants Amphastar access to novel peptides with unique mechanisms that could address poorly treated cancers and offers an alternative to current eye injection...

NasdaqGS:TMCI 1 Year Share Price vs Fair Value Explore Treace Medical Concepts's Fair Values from the Community and...

Trip.com Group (NasdaqGS:TCOM) has quietly caught investors’ attention after a steady recovery from pandemic lows, capped by a rise of nearly 58% over the past year. While there is no single headline grabbing the spotlight this week, the climb in share price may have left many shareholders wondering if the market’s optimism is sustainable or if this is simply a return to the company’s growth narrative as global travel demand rebounds. Looking at the bigger picture, Trip.com Group’s...

NYSE:KOP 1 Year Share Price vs Fair Value Explore Koppers Holdings's Fair Values from the Community and select yours We...

Is On Holding’s Stock Still a Buy? Let’s Break It Down If you’re staring at On Holding’s ticker, wondering what comes next, you’re not alone. The last year has been a rollercoaster for ONON shareholders. The stock has dropped nearly 24% in the past 90 days, even as it’s still up just over 7% compared to a year ago. After such swings, the big question is whether today’s price really reflects the company’s future potential, or if the recent dip is signaling increased risk or uncertainty. Market...

Thinking about what to do with AbbVie stock right now? You are in good company. Whether you already own shares or are just considering a position, it is impossible to ignore how much attention the pharmaceutical giant has been getting lately. AbbVie’s share price has climbed nearly 15% year-to-date, and its performance over the last three and five years has been nothing short of stellar, with total returns surpassing 66% and 168% respectively. Clearly, investors have picked up on something...